Theriva Biologics (NYSEAMERICAN:TOVX) Announces Quarterly Earnings Results

Theriva Biologics (NYSEAMERICAN:TOVX) issued its quarterly earnings data on Wednesday. The company reported ($0.45) earnings per share (EPS) for the quarter, FiscalAI reports.

Theriva Biologics Price Performance

Shares of NYSEAMERICAN:TOVX traded up $0.01 during midday trading on Wednesday, hitting $0.28. 2,362,137 shares of the stock were exchanged, compared to its average volume of 4,805,724. Theriva Biologics has a twelve month low of $0.26 and a twelve month high of $2.08. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average price of $0.39 and a 200-day moving average price of $0.48. The stock has a market cap of $2.72 million, a P/E ratio of -0.01 and a beta of 0.65.

About Theriva Biologics

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company’s lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.